Romiplostim is an antihemorrhagic. This member of the thrombopoietin (TPO) mimetic class is an Fc-peptide fusion protein (peptibody) that activates intracellular transcriptional pathways leading to increased platelet production via the TPO receptor (also known as cMpl), a mechanism analogous to endogenous TPO.
Romiplostim is specifically indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Romiplostim is supplied as sterile solution (250 mcg and 500 mcg) designed for subcutaneous administration.The recommended initial dose of the drug is 1 mcg/kg once weekly based on actual body weight, as a subcutaneous injection.
Source:centerwatch
No comments:
Post a Comment